A citation-based method for searching scientific literature

Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster, David J Lederer, Steven D Nathan, Carlos A Pereira, Steven A Sahn, Robert Sussman, Jeffrey J Swigris, Paul W Noble. N Engl J Med 2014
Times Cited: 1838



Christopher J Ryerson, Eric Vittinghoff, Brett Ley, Joyce S Lee, Joshua J Mooney, Kirk D Jones, Brett M Elicker, Paul J Wolters, Laura L Koth, Talmadge E King, Harold R Collard. Chest 2014
Times Cited: 205




List of shared articles



Times cited

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.
Motoyasu Kato, Shinichi Sasaki, Misa Tateyama, Yuta Arai, Hiroaki Motomura, Issei Sumiyoshi, Yusuke Ochi, Junko Watanabe, Hiroaki Ihara, Shinsaku Togo,[...]. Drug Des Devel Ther 2021
0

Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
Takuma Katano, Akimasa Sekine, Satoshi Ikeda, Hideaki Yamakawa, Toshihiro Misumi, Hiroko Okabayashi, Ryo Okuda, Hideya Kitamura, Tomohisa Baba, Shigeru Komatsu,[...]. Respir Investig 2021
1

Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease.
Kerri A Johannson, Brendan C Lethebe, Deborah Assayag, Jolene H Fisher, Martin Kolb, Julie Morisset, Shane Shapera, Andrea S Gershon, Nathan Hambly, Nasreen Khalil,[...]. Ann Am Thorac Soc 2021
1

Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success.
Giuseppe Brunetti, Alberto Malovini, Mauro Maniscalco, Antonella Balestrino, Mauro Carone, Dina Visca, Armando Capelli, Michele Vitacca, Riccardo Bellazzi, Giancarlo Piaggi,[...]. Respir Med 2021
0

Cost drivers in the pharmacological treatment of interstitial lung disease.
Phillen Nozibuyiso Maqhuzu, Michael Kreuter, Thomas Bahmer, Nicolas Kahn, Martin Claussen, Rolf Holle, Larissa Schwarzkopf. Respir Res 2021
0

Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis.
Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi,[...]. Sci Rep 2021
0